SCHEMBL27029481

SCHEMBL27029481

CC(C)(C)OC(=O)Nc1cc(Cl)nc(N2CCN(C(=O)OC(C)(C)C)CC2)n1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.49
PTPN11 Q06124 1/20 0.48
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
BACE1 P56817 2/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
GPR119 Q8TDV5 3/20 0.43
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PIK3CA P42336 1/20 0.41
POLB P06746 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
SLC2A1 P11166 1/20 0.41
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30718184 1.00 ACHE (0.49) ACHEPTPN11DDB1CRBNBACE1
SCHEMBL29931663 0.91 ACHE (0.42) ACHEPTPN11DDB1CRBNBACE1
SCHEMBL24851896 0.88 GPR119 (0.50) ACHEPTPN11BACE1MEN1KMT2A
SCHEMBL10412083 0.83 MEN1 (0.52) ACHEMEN1KMT2AGPR119MAPT
SCHEMBL30162245 0.83 CKS1B (0.49) ACHEPTPN11MEN1KMT2AGPR119
SCHEMBL24851165 0.83 MEN1 (0.53) ACHEPTPN11MEN1KMT2AGPR119
SCHEMBL24851452 0.83 CKS1B (0.49) ACHEPTPN11MEN1KMT2AGPR119
SCHEMBL18162439 0.83 ACHE (0.47) ACHEPTPN11DDB1CRBNMEN1
SCHEMBL18153356 0.82 SUV39H2 (0.46) ACHEPTPN11MEN1KMT2AGPR119
SCHEMBL29931618 0.82 PIK3CA (0.48) ACHEPTPN11DDB1CRBNMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199654-A1 CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF SUZHOU GUOKUANG PHARMTECH. CO., LTD. (CN) 2024-06-20 US disclosed
EP-4310081-A1 CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF Suzhou Guokuang Pharmtech. Co., Ltd. (CN) 2024-01-24 EP disclosed
EP-4310081-A1 CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF Suzhou Guokuang Pharmtech. Co., Ltd. (CN) 2024-01-24 EP disclosed
CN-117157284-A CTLA-4 small molecule degradation agent and application thereof 苏州国匡医药科技有限公司 2023-12-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199654-A1 CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF CD274, PDCD1, PDCD1LG2 ACHE 3055/4885PTPN11 34/4885DDB1 2112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.